GlassScriptPhysician profile
Betty Hamilton
NPI 1235293572
$56,213.05
in general payments reported to CMS, 2019-2025
11 companies · $4,691 in 2025
The $4,691 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.05 · 2020: $1,000 · 2021: $3,992 · 2022: $14K · 2023: $17K · 2024: $15K · 2025: $4,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $1,981 · Travel and Lodging: $1,606 · Education: $10.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,087.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,175.00 |
| Food and Beverage | $1,981.30 |
| Travel and Lodging | $1,606.41 |
| Education | $10.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $25,585.83 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $19,852.83 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $4,910.30 | 2023 | Cellex, Uvadex |
| Csl Behring | $3,925.00 | 2020-2025 | |
| National Marrow Donor Program | $1,663.15 | 2022-2025 | |
| Genmab U.S., INC. | $115.34 | 2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $99.55 | 2023 | |
| Celgene Corporation | $61.05 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betty Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.